Cerity Partners
NBIX icon

Cerity Partners’s Neurocrine Biosciences NBIX Stock Holding History

Cerity Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.1M Sell
106,678
-17,100
-14% -$2.75M 0.02% 593
2026
Q2 		$20.9M Sell
123,778
-20,751
-14% -$3.08M 0.03% 471
2026
Q1 		$19M Buy
144,529
+10,770
+8% +$1.43M 0.03% 461
2025
Q4 		$19M Buy
133,759
+30,133
+29% +$4.37M 0.03% 428
2025
Q3 		$14.5M Buy
103,626
+44,852
+76% +$6.08M 0.02% 458
2025
Q2 		$7.39M Buy
58,774
+25,413
+76% +$2.91M 0.01% 650
2025
Q1 		$3.69M Sell
33,361
-8,376
-20% -$1.06M 0.01% 850
2024
Q4 		$5.29M Buy
41,737
+2,713
+7% +$336K 0.01% 691
2024
Q3 		$4.5M Buy
39,024
+11,622
+42% +$1.59M 0.01% 734
2024
Q2 		$3.77M Sell
27,402
-1,354
-5% -$186K 0.01% 694
2024
Q1 		$3.97M Buy
28,756
+24,392
+559% +$3.33M 0.01% 723
2023
Q4 		$575K Buy
+4,364
New +$502K ﹤0.01% 1212
2023
Q3 		– Sell
-4,214
Closed -$397K – 1607
2023
Q2 		$397K Buy
4,214
+365
+9% +$35.7K ﹤0.01% 1280
2023
Q1 		$390K Buy
3,849
+610
+19% +$63.5K ﹤0.01% 1411
2022
Q4 		$387K Buy
3,239
+533
+20% +$62.4K ﹤0.01% 1052
2022
Q3 		$288K Sell
2,706
-202
-7% -$20.5K ﹤0.01% 910
2022
Q2 		$284K Buy
+2,908
New +$268K ﹤0.01% 928

Other funds holding NBIX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Cerity Partners's NBIX Position: Q3 2026 in Review

Cerity Partners reduced its Neurocrine Biosciences (NBIX) stake by 14% in Q3 2026, selling an estimated $2.75M and leaving 106,678 shares worth $15.1M. The position accounts for 0.02% of the portfolio, ranked #593.

Cerity Partners first reported a position in NBIX in Q2 2022 and has held it in 17 quarters since. The position peaked at $20.9M in Q2 2026. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Cerity Partners held 106,678 shares of Neurocrine Biosciences worth $15.1M as of Q3 2026.
  • Cerity Partners sold 17,100 Neurocrine Biosciences shares in Q3 2026, an estimated $2.75M.
  • Neurocrine Biosciences made up 0.02% of Cerity Partners's portfolio in Q3 2026, its #593 holding.
  • Cerity Partners first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 17 quarters since.
  • Cerity Partners's Neurocrine Biosciences position peaked at $20.9M in Q2 2026.
  • 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Cerity Partners's 13F filing for Q3 2026, filed 13 Nov 2026.